SML3344
Vosoritide Trifluoroacetate
≥95% (HPLC)
别名:
BMN 111 Trifluoroacetate, PGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC Trifluoroacetate, cyclic (23→39)-disulfide L-prolylglycyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-prolyl-L-asparaginyl-L-alanyl-L-arginyl-L-lysyl-L-tyrosyl-L-lysylglycyl-Lalanyl-L-asparaginyl-L-lysyl-L-lysylglycyl-L-leucyl-L-seryl-L-lysylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-leucyl-L-lysyl-L-leucyl-L-α-aspartyl-L-arginyl-L-isoleucylglycyl-L-seryl-L-methionyl-L-serylglycyl-L-leucylglycyl-L-Cysteine Trifluoroacetate
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C176H290N56O51S3 · xC2HF3O2
分子量:
4102.73 (free base basis)
NACRES:
NA.77
UNSPSC Code:
12352200
Assay:
≥95% (HPLC)
Form:
powder
Biochem/physiol Actions
More stable analogue of human C-type natriuretic peptide (CNP)
Vosoritide is a more stable analogue of human C-type natriuretic peptide (CNP). Vosoritide binds to the Natriuretic-Peptide Receptor B (NPR B), which leads to MAPK pathway inhibition and an increased production of Extracellular Matrix. It reduces the achondroplastic phenotype. Vosoritide is approved for treatment of Achondroplasia aged 5 and up.
存储类别
11 - Combustible Solids
wgk
WGK 3